Keyphrases
United Kingdom
100%
Pediatric
100%
Disease-modifying Therapy
100%
Relapsing-remitting multiple Sclerosis
100%
New Disease
66%
Radiologic
33%
Clinical Relapse
25%
Time to Relapse
16%
Adjusted Hazard Ratio
16%
Annualized Relapse Rate
16%
Expanded Disability Status Scale
16%
MRI Lesions
16%
Relapse Time
16%
Medical Records
8%
Low Risk
8%
Cognitive Impairment
8%
Interferon-β (IFN-β)
8%
Potential Confounders
8%
Multivariable
8%
Treatment Initiation
8%
Switching Time
8%
Glatiramer Acetate
8%
Real-world Effectiveness
8%
Paraclinical
8%
Time-to-treatment
8%
Retrospective multicenter Study
8%
Inflammatory Demyelination
8%
Switching Treatment
8%
MRI Activity
8%
MRI Changes
8%
Medicine and Dentistry
Pediatrics
100%
Multiple Sclerosis
100%
Disease Modifying Therapy
100%
Magnetic Resonance Imaging
25%
Hazard Ratio
16%
Recurrence Risk
16%
Expanded Disability Status Scale
16%
Infusion
8%
Cognitive Defect
8%
Medical Record
8%
Demyelination
8%
Beta Interferon
8%
Glatiramer
8%
Time to Treatment
8%
Neuroscience
Relapsing Remitting Multiple Sclerosis
100%
Magnetic Resonance Imaging
75%
Expanded Disability Status Scale
50%
Cognitive Disorders
25%
Glatiramer Acetate
25%
Beta Interferon
25%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Diseases
100%
Recurrence Risk
16%
Expanded Disability Status Scale
16%
Cognitive Defect
8%
Glatiramer
8%
Beta Interferon
8%
Demyelination
8%